PIK3CA and diffuse large B-cell lymphoma: Given PI3K-AKT dependency in DLBCL, combination of capivasertib and venetoclax along with an anti-CD20 antibody, rituximab could present a unique therapeutic opportunity for patients with relapse/refractory DLBCL [24–27].